Prevent diaphragm weakness after esophagus surgery
Treatments studied
Part of Lungs & breathing clinical trials.
This trial studies a medicine that blocks Janus kinase (JAK) signals, to help prevent breathing muscle weakness in the diaphragm after esophagus removal surgery. It may help patients who need a ventilator during recovery avoid “ventilator-induced” diaphragm dysfunction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for an esophagectomy (esophagus removal surgery).
- Your lung problems are no worse than mild.
- You do not have a nerve or muscle disorder that could weaken your diaphragm.
- Your liver and kidney tests are normal or acceptable for the study.
- You are not taking immune-suppressing medicines (including prednisone) or antifungal medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
This study looks at how often the diaphragm (the main breathing muscle) weakens after lung surgery done without a breathing tube. It aims to help doctors understand recovery and prevent future breathing problems.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This trial tests the drug tofacitinib in children with juvenile idiopathic arthritis (a type of arthritis that starts before age 18). It looks at whether tofacitinib is a safe and effective treatment for this condition.
Hear when a new Diaphragm Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.